2. “Regenerative Medicine” Some success stories!
(Part-III)
“Regenerative Medicine” Some success stories!

3. 1. Applying Regenerative Medicine to Bladder
2/6/12

4. Applying Regenerative Medicine to Bladder
Neurogenic bladder disorder, for example.
Cystoplasty; a surgical treatment.
What we did???
Human bladder was engineered!

5. How??? Perform bladder biopsy; for urothelial and muscle cells.
In vitro culturing and expansion of cells.
Seeding of cells on a biodegradable bladder-shaped scaffold.
New organ was ready after 8 weeks.

6. Regenerated bladder

7. Contd… 5. Anastomosis 6. Apply fibrin glue. 7. Omental wrapping.

8. Omentum layer

9. Omental wrapping

10. Results After 46 months: Improved function & capacity of ureter.
Renal function was normal through out the follow up.
No metabolic complication occured.

11. Positives:
No immuno-suppression required!
Negatives:
No immediate Reconstruction of Vascular supply.
Instant Oxygen and nutrients supply is by diffusion.
Inflammation before re-angiogenesis.

12. 2. Applying Regenerative Medicine to Upper Airways
2/6/12

13. 2. Applying Regenerative Medicine to Upper Airways
End stage bronchio-malacia in a 30 year old woman, for example.
What we did???
Ex- vivo bioengineering of trachea.

14. How??? Retrieving of deceased donor trachea. Decellularization.
Obtaining epithelial cells from bronchial mucosa.
Isolation of stem cells from patient’s bone marrow.
Differentiation of SCs into chondrocytes.
4 days maturation.
Human trachea was used as natural scaffold.
Seeding with autologous epithelial cells and chondrocytes.
Implantation of construct to replace the diseased one.

15. Trachea scaffold

16. Culturing the trachea

17. Results After 18 months: Imaging showed normal architecture.
Patient was doing well.
Advantage!
Use of natural/ human scaffold.

18. But Behave!!

19. “Not all offices have science fellows.”

20. Ethical issues About: Moral status of the embryo for ESCs.
Completely Informed consent of patient required.
Enrollment of subjects for clinical trials.
Protecting the rights and welfare of human subjects.
Resource allocation & cost.
Intellectual property considerations.

21. Thanks! 
2/6/12